Radiopharm Theranostics Limited (RADX)

Radiopharm Theranostics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Net Income	-	-38.34	-47.95	-34.61	-30.42
Depreciation & Amortization	-	2.6	3.13	3.3	2.98
Stock-Based Compensation	-	1.9	2.64	3.04	4.8
Other Adjustments	-	3.09	12.15	1.13	10.48
Change in Receivables	-	-9.41	3.48	1.51	-0.05
Changes in Accounts Payable	-	0.51	3.5	2.35	2.53
Changes in Other Operating Activities	-21.95	-33.7	-22.9	-23.11	-10.14
Operating Cash Flow	-36.87	-36.65	-22.98	-23.2	-9.91
Capital Expenditures	-	-	-	-0.05	-0
Purchases of Intangible Assets	-	-	-	-	-28.34
Proceeds from Sale of Intangible Assets	-	3	-	-1.49	-
Purchases of Investments	-	-	-	-	-0.04
Other Investing Activities	-	-1.23	-0.32	-	-
Investing Cash Flow	-	1.77	-0.32	-1.53	-28.38
Long-Term Debt Issued	-	-	7.37	-	0.01
Long-Term Debt Repaid	-	-3.59	-5.17	-	-0.07
Net Long-Term Debt Issued (Repaid)	-	-3.59	2.2	-	-0.06
Issuance of Common Stock	-	53.98	29.65	10.07	70
Net Common Stock Issued (Repurchased)	-	53.98	29.65	10.07	70
Other Financing Activities	-0.76	-4.96	-1.65	-0.85	-4.83
Financing Cash Flow	-1.04	45.43	30.2	9.22	65.11
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.32	-0.01	-0.03	0.23	0.13
Net Cash Flow	-38.23	10.56	6.9	-15.51	26.82
Free Cash Flow	-36.87	-36.65	-22.98	-23.25	-9.91
FCF Margin	-	-1008.57%	-7678.40%	-7951.56%	-
Free Cash Flow Per Share	-3.42	-5.28	-17.84	-22.80	-16.40
Levered Free Cash Flow	-21.95	-72.52	-62.02	-52.12	-35.1
Unlevered Free Cash Flow	-21.95	-68.86	-63.58	-52.03	-25.68

Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q